These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24456624)

  • 1. Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study.
    Iaria ML; Fiorentini S; Focà E; Zicari S; Giagulli C; Caccuri F; Francisci D; Di Perri G; Castelli F; Baldelli F; Caruso A
    Vaccine; 2014 Feb; 32(9):1072-8. PubMed ID: 24456624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
    Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
    Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope.
    Focà E; Iaria ML; Caccuri F; Fiorentini S; Motta D; Giagulli C; Castelli F; Caruso A
    HIV Clin Trials; 2015 Aug; 16(4):157-62. PubMed ID: 26057863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
    Fiorentini S; Marsico S; Becker PD; Iaria ML; Bruno R; Guzmán CA; Caruso A
    Vaccine; 2008 Aug; 26(36):4758-65. PubMed ID: 18602957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
    Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
    Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical studies on immunogenicity and safety of the HIV-1 p17-based synthetic peptide AIDS vaccine--HGP-30-KLH.
    Naylor PH; Sztein MB; Wada S; Maurer S; Holterman D; Kirkley JE; Naylor CW; Zook BC; Hitzelberg RA; Gibbs CJ
    Int J Immunopharmacol; 1991; 13 Suppl 1():117-27. PubMed ID: 1823903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
    Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
    AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.
    Sarin PS; Mora CA; Naylor PH; Markham R; Schwartz D; Kahn J; Heseltine P; Gazzard B; Youle M; Rios A
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):401-7. PubMed ID: 7580834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
    Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
    AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PEDVAC trial: preliminary data from the first therapeutic DNA vaccination in HIV-infected children.
    Palma P; Romiti ML; Li Pira G; Montesano C; Mora N; Aquilani A; Santilli V; Tchidjou HK; Ivaldi F; Giovannelli L; Pontrelli G; Borra G; Blomberg P; Gudmundsdotter L; Bråve A; Montano M; Bernardi S; Manca F; Wahren B; Rossi P
    Vaccine; 2011 Sep; 29(39):6810-6. PubMed ID: 21216310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects.
    Vardas E; Stanescu I; Leinonen M; Ellefsen K; Pantaleo G; Valtavaara M; Ustav M; Reijonen K
    Vaccine; 2012 Jun; 30(27):4046-54. PubMed ID: 22549090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue sub-unit vaccine in seronegative subjects.
    Kahn JO; Stites DP; Scillian J; Murcar N; Stryker R; Volberding PA; Naylor PH; Goldstein AL; Sarin PS; Simmon VF
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1321-5. PubMed ID: 1466950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.
    Ensoli F; Cafaro A; Casabianca A; Tripiciano A; Bellino S; Longo O; Francavilla V; Picconi O; Sgadari C; Moretti S; Cossut MR; Arancio A; Orlandi C; Sernicola L; Maggiorella MT; Paniccia G; Mussini C; Lazzarin A; Sighinolfi L; Palamara G; Gori A; Angarano G; Di Pietro M; Galli M; Mercurio VS; Castelli F; Di Perri G; Monini P; Magnani M; Garaci E; Ensoli B
    Retrovirology; 2015 Apr; 12():33. PubMed ID: 25924841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial.
    Thacher EG; Cavassini M; Audran R; Thierry AC; Bollaerts A; Cohen J; Demoitié MA; Ejigu D; Mettens P; Moris P; Ofori-Anyinam O; Spertini F
    AIDS; 2014 Jul; 28(12):1769-81. PubMed ID: 24911353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects.
    Goldstein G; Chicca JJ
    Hum Vaccin Immunother; 2012 Apr; 8(4):479-85. PubMed ID: 22336878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.